Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Cardiovascular Drugs: Classification based on Therapeutic Indications01:18

Cardiovascular Drugs: Classification based on Therapeutic Indications

Cardiovascular diseases, encompassing a range of conditions, can significantly affect the heart's operations and the overall circulatory system. These conditions impair the heart's ability to pump blood, leading to a deficit in oxygen supply to crucial organs. Anomalies in the heart's electrical system, known as arrhythmias, can cause heartbeats to accelerate or slow down. Usually, heart rates increase during physical activity and decrease while resting or sleeping. However, frequent irregular...
Introduction Cardiac Emergencies01:30

Introduction Cardiac Emergencies

Cardiac emergencies are critical situations involving the heart that require immediate medical intervention to prevent severe complications or death. These emergencies often arise from underlying heart conditions that impair the heart's ability to function correctly.Types of Cardiac EmergenciesThe most common types of cardiac emergencies include Acute Coronary Syndrome (ACS), myocardial infarction (MI), cardiac arrest, and heart failure.Acute Coronary Syndrome (ACS)Acute Coronary Syndrome (ACS)...
Ischemic Heart Disease: Overview01:17

Ischemic Heart Disease: Overview

Ischemic heart disease occurs when the heart's blood supply dwindles, causing an ominous lack of oxygen and nutrients. This deficiency, stemming from reduced or obstructed blood flow, spells danger, leading to heart muscle damage and dysfunction.
Atherosclerosis, the primary malefactor, orchestrates this dangerous condition. It manifests as the accumulation of fatty deposits, akin to insidious plaques, within arterial walls. As time elapses, these plaques metamorphose, hardening and narrowing...
Coronary Artery Disease I: Introduction01:30

Coronary Artery Disease I: Introduction

Coronary Artery Disease (CAD): An Overview with Scientific InsightsCoronary Artery Disease (CAD), often referred to as C-A-D, is a prevalent blood vessel disorder classified under the broader category of atherosclerosis. Atherosclerosis is a pathological process characterized by the hardening and narrowing of arteries due to the accumulation of atherosclerotic plaques. These plaques are composed of cholesterol, fatty substances, inflammatory cells, calcium, and fibrin, reducing blood flow to...
Cardiomyopathy I: Introduction and Classification01:25

Cardiomyopathy I: Introduction and Classification

Cardiomyopathy, or CMP, is a group of diseases affecting the myocardial structure, impairing its ability to pump blood effectively. This condition can lead to arrhythmias, heart failure, or sudden cardiac death.Cardiomyopathies are classified into primary and secondary categories:Primary Cardiomyopathy refers to conditions involving only the heart muscle that are often idiopathic (of unknown cause) or genetic. They primarily affect the myocardium without the involvement of other systemic...
Heart Failure I: Introduction01:27

Heart Failure I: Introduction

Heart failure refers to a clinical syndrome caused by structural or functional cardiac disorders that prevent the heart from pumping an adequate amount of blood to meet the body's metabolic needs. This condition often arises from myocardial infarction or ischemia, leading to decreased cardiac output, reduced tissue perfusion, impaired gas exchange, fluid volume imbalance, and decreased functional ability.Heart failure can result from disruptions in the mechanisms that regulate cardiac output...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Bioactive lipids in plasma and atherogenic apoB-containing lipoproteins: Effects of statins and PCSK9 inhibitors and relevance to residual cardiovascular risk.

Pharmacology & therapeutics·2026
Same author

Triglyceride-rich lipoproteins, remnants and atherosclerotic cardiovascular disease: What we know and what we need to know.

Atherosclerosis·2025
Same author

Editorial: The Brussels International Declaration on Lp(a) Testing And Management-A call to action.

Atherosclerosis·2025
Same author

Therapeutic PCSK9 targeting: Inside versus outside the hepatocyte?

Pharmacology & therapeutics·2025
Same author

Plasma Triglyceride Reduction and Cardiovascular Risk in ODYSSEY Outcomes Trial: Interpret With Caution.

Journal of the American College of Cardiology·2025
Same author

Differentiating EPA from EPA/DHA in cardiovascular risk reduction.

American heart journal plus : cardiology research and practice·2024
Same journal

'Diet and lifestyle' in the management of dyslipidaemia and prevention of CVD - Understanding the level of knowledge and interest of European Atherosclerosis Society members.

Atherosclerosis. Supplements·2021
Same journal

Improving lipid management in patients with acute coronary syndrome: The ACS Lipid EuroPath tool.

Atherosclerosis. Supplements·2021
Same journal

Lipid Clinics Network. Rationale and design of the EAS global project.

Atherosclerosis. Supplements·2021
Same journal

Implementation of clinical practices and pathways optimizing ACS patients lipid management: Focus on eight European initiatives.

Atherosclerosis. Supplements·2021
Same journal

Lipid-lowering therapy and low-density lipoprotein cholesterol goal achievement in patients with acute coronary syndromes: The ACS patient pathway project.

Atherosclerosis. Supplements·2021
Same journal

Prevalence and relationship between metabolic syndrome and risk of cardiovascular disease: Evidence from two population-based studies.

Atherosclerosis. Supplements·2021
See all related articles

Related Experiment Video

Updated: Jun 5, 2026

Hydra, a Computer-Based Platform for Aiding Clinicians in Cardiovascular Analysis and Diagnosis
07:51

Hydra, a Computer-Based Platform for Aiding Clinicians in Cardiovascular Analysis and Diagnosis

Published on: September 26, 2018

Cardiovascular diseases. Introduction.

M John Chapman1

  • 1Institut National de la Santé et de la Recherche Médicale (INSERM) UMR-S939, Pavillon Benjamin Delessert, Hôpital de la Pitié, 83 Blvd l'Hôpital, 75651 Paris Cedex 13, France. john.chapman@upmc.fr

Atherosclerosis. Supplements
|January 4, 2011
PubMed
Summary
This summary is machine-generated.

Dyslipidaemia significantly increases cardiovascular disease risk. Effective management, particularly lowering low-density lipoprotein-cholesterol (LDL-C) with statins like pitavastatin, is crucial for reducing mortality and vascular events.

More Related Videos

Optical Coherence Tomography Based Biomechanical Fluid-Structure Interaction Analysis of Coronary Atherosclerosis Progression
13:07

Optical Coherence Tomography Based Biomechanical Fluid-Structure Interaction Analysis of Coronary Atherosclerosis Progression

Published on: January 15, 2022

Related Experiment Videos

Last Updated: Jun 5, 2026

Hydra, a Computer-Based Platform for Aiding Clinicians in Cardiovascular Analysis and Diagnosis
07:51

Hydra, a Computer-Based Platform for Aiding Clinicians in Cardiovascular Analysis and Diagnosis

Published on: September 26, 2018

Optical Coherence Tomography Based Biomechanical Fluid-Structure Interaction Analysis of Coronary Atherosclerosis Progression
13:07

Optical Coherence Tomography Based Biomechanical Fluid-Structure Interaction Analysis of Coronary Atherosclerosis Progression

Published on: January 15, 2022

Area of Science:

  • Cardiology and clinical pharmacology.
  • Lipid metabolism and cardiovascular risk assessment.

Background:

  • Cardiovascular diseases (CVDs) are a leading cause of global mortality, with dyslipidaemia (elevated apolipoprotein B:apoA1 ratio) being a major modifiable risk factor.
  • Lowering low-density lipoprotein-cholesterol (LDL-C) via statin therapy is a cornerstone in managing dyslipidaemia and reducing cardiovascular risk, as evidenced by meta-analyses showing significant mortality and event reduction per LDL-C decrease.

Discussion:

  • International guidelines advocate for strict LDL-C targets in patients with established CVDs and those at high risk.
  • Pitavastatin, a commonly used statin in several Asian countries and recently approved in the USA, is reviewed for its safety and efficacy.
  • Comparative analysis of pitavastatin against other statins (atorvastatin, simvastatin, pravastatin) is presented, alongside an examination of its benefits beyond LDL-C reduction.

Key Insights:

  • Statin therapy, specifically reduction of LDL-C, demonstrably lowers all-cause mortality, coronary mortality, and major vascular events.
  • Pitavastatin's efficacy and safety profile are evaluated in the context of established treatment guidelines and compared to other widely used statins.
  • The review explores potential additional therapeutic benefits of pitavastatin that extend beyond its lipid-lowering effects.

Outlook:

  • Pitavastatin's expanding availability in Western markets suggests a growing role in clinical practice for dyslipidaemia management.
  • Further research may elucidate pitavastatin's unique advantages and optimize its application in diverse patient populations.
  • The findings support evidence-based recommendations for statin selection in cardiovascular risk reduction strategies.